Company: AEMD
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001683168-25-008271
Chunk: 60

Company: AETHLON MEDICAL INC
Filing Date: 2025-11-12
Form: 10-Q
Item: Item 8
Chunk 60
---
acellular vesicles (EVs), including those derived
from platelets, which are implicated in cancer, autoimmune disease, and neurological disorders. The study demonstrated >98% removal
of platelet-derived EVs from healthy human plasma in a simulated clinical session.

In August 2025, we presented a poster at the Keystone
Symposium on Long COVID and Other Post-Acute Infection Syndromes in Santa Fe, New Mexico. In collaboration with investigators at the University
of California, San Francisco Medical Center Long COVID Clinic, we analyzed samples from participants with Long COVID and from recovered
individuals as controls. Data presented at the symposium showed that both large and small EVs from Long COVID participants bound to the
GNA lectin and to the Hemopurifier’s lectin affinity resin, supporting the potential utility of the device in this patient population.
The full poster presentation is available on our website.

These exploratory programs, together with our
academic collaborations, are intended to inform potential future clinical indications and expand the utility of the Hemopurifier platform.

We have sufficient inventory of Hemopurifiers
to support our ongoing oncology trial in Australia as well as any near-term expansion of that study or potential trial activity in India.
While we have received FDA approval to begin manufacturing at our San Diego facility under our IDE supplement, we are still awaiting FDA
approval of a separate supplement to qualify an additional supplier of a key Hemopurifier component. We continue to work with the FDA
on this process.

Successful outcomes of human trials will also
be required by the regulatory agencies of certain foreign countries where we plan to market and sell the Hemopurifier. Some of our patents
may expire before FDA approval or approval in a foreign country, if any, is obtained. However, we believe that certain patent applications
and/or other patents issued to us more recently will help protect the proprietary nature of our Hemopurifier treatment technology.

In addition to the foregoing, we are monitoring
closely the impact of inflation, recent bank failures and the war between Russia and Ukraine and the military conflicts in Israel and
the surrounding areas, as well as related political and economic responses and counter-responses by various global factors on our business.
Given the level of uncertainty regarding the duration and impact of these events on capital markets and the U.S. economy, we are unable
to assess the impact on our timelines and future access to capital. The full extent to which inflation, recent bank failures and the ongoing
m